Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Virol J ; 20(1): 170, 2023 08 02.
Artigo em Inglês | MEDLINE | ID: mdl-37533069

RESUMO

Viral infections of the central nervous system (CNS) are common worldwide and result in considerable morbidity and mortality associated with neurologic illness. Until now, there have been no epidemiologic data regarding viruses causing aseptic meningitis, encephalitis, and CNS infections in Egypt. We investigated 1735 archived cerebrospinal fluid samples collected from Egyptian patients between 2016 and 2019 and performed molecular characterization for infection for12 different viruses: herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesviruses 6 and 7 (HHV-6 and HHV-7), human enteroviruses (HEVs), human parechovirus (HPeV), parvovirus B19 (B19V), adenovirus (AdV), and mumps virus (MuV). All included samples were negative for bacterial infection. Our results indicated a relatively high prevalence of viral infection, with HEVs being the most prevalent viruses, followed by HSV-1, EBV, and then HSV-2. The highest prevalence was among male patients, peaking during the summer. Data obtained from this study will contribute to improving the clinical management of viral infections of the CNS in Egypt.


Assuntos
Infecções do Sistema Nervoso Central , Enterovirus , Infecções por Vírus Epstein-Barr , Viroses , Vírus , Humanos , Masculino , Egito/epidemiologia , Herpesvirus Humano 4/genética , Reação em Cadeia da Polimerase/métodos , Viroses/epidemiologia , Infecções do Sistema Nervoso Central/epidemiologia , Herpesvirus Humano 3/genética , Herpesvirus Humano 2 , DNA Viral
2.
BMC Infect Dis ; 23(1): 542, 2023 Aug 18.
Artigo em Inglês | MEDLINE | ID: mdl-37596534

RESUMO

BACKGROUND: The o severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has killed millions of people and caused widespread concern around the world. Multiple genetic variants of SARS-CoV-2 have been identified as the pandemic continues. Concerns have been raised about high transmissibility and lower vaccine efficacy against omicron. There is an urgent need to better describe how omicron will impact clinical presentation and vaccine efficacy. This study aims at comparing the epidemiologic, clinical, and genomic characteristics of the omicron variant prevalent during the fifth wave with those of other VOCs between May 2020 and April 2022. METHODS: Epidemiological data were obtained from the National Electronic Diseases Surveillance System. Secondary data analysis was performed on all confirmed COVID-19 patients. Descriptive data analysis was performed for demographics and patient outcome and the incidence of COVID-19 was calculated as the proportion of SARS-CoV-2 confirmed patients out of the total population of Egypt. Incidence and characteristics of the omicron cohort from January- April 2022, were compared to those confirmed from May 2020-December 2021. We performed the whole-genome sequencing of SARS-CoV-2 on 1590 specimens using Illumina sequencing to describe the circulation of the virus lineages in Egypt. RESULTS: A total of 502,629 patients enrolled, including 60,665 (12.1%) reported in the fifth wave. The incidence rate of omicron was significantly lower than the mean of incidences in the previous subperiod (60.1 vs. 86.3/100,000 population, p < 0.001). Symptoms were reported less often in the omicron cohort than in patients with other variants, with omicron having a lower hospitalization rate and overall case fatality rate as well. The omicron cohort tended to stay fewer days at the hospital than did those with other variants. We analyzed sequences of 2433 (1590 in this study and 843 were obtained from GISAID platform) Egyptian SARS-CoV-2 full genomes. The first wave that occurred before the emergence of global variants of concern belonged to the B.1 clade. The second and third waves were associated with C.36. Waves 4 and 5 included B.1.617.2 and BA.1 clades, respectively. CONCLUSIONS: The study indicated that Omicron-infected patients had milder symptoms and were less likely to be hospitalized; however, patients hospitalized with omicron had a more severe course and higher fatality rates than those hospitalized with other variants. Our findings demonstrate the importance of combining epidemiological data and genomic analysis to generate actionable information for public health decision-making.


Assuntos
COVID-19 , SARS-CoV-2 , Humanos , SARS-CoV-2/genética , COVID-19/epidemiologia , Egito/epidemiologia , Gravidade do Paciente , Evolução Molecular
3.
Int J Biol Macromol ; 190: 927-939, 2021 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-34480910

RESUMO

The incorporation between nano-polyvinyl alcohol (PVA) and nano-chitosan (Cs) to produce sandwich nanohybrid (SNH) for water treatment and improvement the adsorption of sofosbuvir drug (SOF). The photocatalytic activity and formation of reactive oxygen species (ROS) were detected with oxidation of organic dyes such as Rhodamine B (RhB), methylene blue (MB), and methyl orange (MO). The effect of SNH on the release of SOF in blood and inside the cells at pH 7.4 and pH 6.8, respectively were observed by UV-Visible spectroscopy (UV-Vis). The binding constant (Kb) was reported at 0.0035 min-1 and the loading constant at 0.0024 min-1, while the release efficiency was 42.6% at pH 7.4 and 74.7% at pH 6.8. The efficiency of photocatalytic activity against organic dyes MO, MB, and RhB are detected at 2.4% and 1%, and 42%, respectively. The cytotoxicity of SNH has been observed with MDA-MB-231 and HepG2 cell line with three concentrations of SNH, where the little concentration has low effect on the HepG2 and high viability, this result was reversed with the high concentration, also the yellow color due to the lysis of the cells. The antioxidant of the SNH was detected by FRAP technique.


Assuntos
Quitosana/química , Sistemas de Liberação de Medicamentos , Hepacivirus/fisiologia , Nanopartículas/química , Álcool de Polivinil/química , Sofosbuvir/farmacologia , Água/química , Antioxidantes/farmacologia , Calibragem , Catálise , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Hepacivirus/efeitos dos fármacos , Humanos , Fenômenos Ópticos , Rodaminas/química , Sofosbuvir/química , Espectrofotometria Ultravioleta , Espectroscopia de Infravermelho com Transformada de Fourier , Eletricidade Estática
4.
Spectrochim Acta A Mol Biomol Spectrosc ; 261: 120008, 2021 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-34087770

RESUMO

Self-assembly of Sofosbuvir drug (SOF) anti-hepatitis C virus (HCV) with bio-polymeric nanoparticles such as chitosan nanoparticles (Cs NPs) and polyvinyl alcohol nanoparticles (PVA NPs), the novel composites have been characterized successfully by different analysis such as Energy-dispersive X-ray spectroscopy (EDX), Scanning electron microscopy (SEM), UV-Visible spectrophotometer (UV-Vis) and Fourier Transmittance Infrared (FT-IR). The improvement of the Sofosbuvir effect as a result of loading drug on the bio-polymer NPs surface has been detected by the UV-Vis, and fluorescence spectroscopy techniques. The improvement of SOF efficiency was revealed via studying the drug release of SOF from biopolymers NPs surface at pH 7.4, UV-Vis spectra used for the releasing process. The binding constant (Kb) value was reported at 0.000055 and 0.3613 min-1 for Cs and PVA NPs respectively. Also, the value of KSV was documented at 0.0014 and 7.16 min-1 for Cs@SOF and PVA@SOF hybrid nanocomposite. The incorporation rate (k) of SOF on the surface of biopolymer nano molecules was calculated to be 0.00812 and 0.0165 min-1 for Cs and PVA NPs, respectively. Besides the observed value of (n) was close to the unit 0.74 and 0.86 for Cs and PVA NPs, respectively. The SOF released from Cs NPs surface was documented at 0.09 mg after 24 h, while PVA NPs reported at 0.7 mg at the same time and the release efficiency is 56.5 and 73% for Cs@SOF and PVP@SOF, respectively. From the results, we suggest Cs/SOF and PVA/SOF hybrid nanocomposites have spectroscopic results that make them promising candidate drugs, but need to the clinical trials.


Assuntos
Quitosana , Nanopartículas , Preparações Farmacêuticas , Liberação Controlada de Fármacos , Polímeros , Sofosbuvir , Espectroscopia de Infravermelho com Transformada de Fourier
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA